Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Is sivextro effective against mrsa?

See the DrugPatentWatch profile for sivextro

Does Sivextro Work Against MRSA?


Sivextro (tedizolid phosphate) is effective against methicillin-resistant Staphylococcus aureus (MRSA), including strains resistant to linezolid. It inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, with in vitro minimum inhibitory concentrations (MICs) typically ≤0.5 μg/mL for MRSA isolates.[1][2] Clinical trials showed 92-96% success rates in treating acute bacterial skin and skin structure infections (ABSSSI) caused by MRSA, comparable to linezolid.[3]

How Does Sivextro Compare to Linezolid for MRSA?


Sivextro has similar MRSA efficacy to linezolid but requires only 200 mg once daily for 6 days versus linezolid's 600 mg twice daily for 10 days. Both achieve clinical cure rates around 90-95% at end-of-therapy for MRSA ABSSSI, though Sivextro shows slightly lower hematologic toxicity like thrombocytopenia.[1][4] No head-to-head superiority trials exist for MRSA pneumonia.

What Infections Does Sivextro Treat with MRSA Coverage?


FDA approves Sivextro for ABSSSI in adults, where MRSA is common. It covers MRSA skin infections like cellulitis and abscesses but lacks approval for MRSA bacteremia, pneumonia, or osteomyelitis. Off-label use occurs in some MRSA cases, supported by susceptibility data.[2][5]

MRSA Resistance to Sivextro?


MRSA resistance to Sivextro emerges slowly; cross-resistance with linezolid is rare but possible via cfr genes. Surveillance data from 2010-2020 show <1% of MRSA isolates resistant.[1][6] Shorter treatment duration may reduce resistance risk versus linezolid.

Who Should Avoid Sivextro for MRSA?


Avoid in patients with known tedizolid hypersensitivity or severe hepatic impairment. Monitor for myelosuppression in long-term use; it's pregnancy category C. Drug interactions include strong CYP3A4 inducers reducing levels.[5]

[1]: FDA Label for Sivextro
[2]: DrugPatentWatch.com - Tedizolid Patent and Susceptibility Data
[3]: Prokocimer P et al. N Engl J Med. 2013;368(5):518-26.
[4]: Lodise TP et al. Clin Infect Dis. 2016;62(6):697-705.
[5]: Sivextro Prescribing Information
[6]: Zhanel GG et al. Drugs. 2015;75(5):591-602.



Other Questions About Sivextro :

What is the success rate of sivextro for skin infections? What is sivextro? What is the dose of sivextro for skin and soft tissue infections? Sivextro normal duration of therapy? What is the dosing frequency for sivextro for skin infections? How is sivextro administered? Sivextro patent?